Fig. 1.

The STEP inhibitor TC-2153 prevents PCP-induced decrease in BDNF signaling. a Cortical cultures were pretreated with vehicle or TC-2153 (1 μM) 1 h prior to PCP treatment (10 μM for 24 h). Cells were lysed and subjected to Western blotting. Proteins were probed with phospho-specific- or pan-antibodies, and phospho-levels were normalized to total protein levels, and then to β-actin as loading control. BDNF levels in cell lysates (b) and culture medium (c) were assayed with ELISA. d mRNA levels of 3 BDNF transcripts (Exon I, IV, and VI) were measured with quantitative real-time PCR. Target expression levels were normalized to GAPDH as internal control. Experimental data were compared to controls and expressed as mean ± SEM. Statistical significance was determined with one-way ANOVA with post hoc Bonferroni’s test (*p < 0.05, **p < 0.01, n = 6 independent batches of cultures for a–d)